Loading data for VSTM — first visit, this takes a few seconds.
Verastem, Inc. (VSTM)
NasdaqCM: VSTM
· 实时价格 · USD
8.20
+0.22 (2.76%)
收盘价： Sep 08, 2026, 8:00 PM
8.20
+1.49%
盘后: 6:07 PM
股价、关键数字和最新消息，都在这一页。
Verastem, Inc.（VSTM）股价、分析与数据
暂无数据
| 买价 | 7.24 |
| 市值 | 732M |
| 营收（TTM） | 87.5M |
| 净利润（TTM） | -203M |
| 0.32 | |
| -2.44 | |
| n/a | |
| -10.77 | |
| 市净率（TTM） | 8.68 |
| 市销率（TTM） | 8.36 |
| 财报日期 | Nov 3, 2026 |
| 卖价 | 7.86 |
| 成交量 | 2,301,509 |
| 20日均量 | 2,454,633 |
| 开盘价 | 7.91 |
| 前收盘价 | 7.98 |
| 日内区间 | 7.72 - 8.21 |
| 52周区间 | 3.43 - 10.82 |
| 分析师 | n/a |
| 目标价 | n/a |
| 分红 | n/a |
| 除息日 | n/a |
关于 VSTM
Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, which is an orally administered, small molecule dual RAF/MEK inhibitor developed to block MEK kinase activity and the compensatory reactivation of MEK by upstream RAF, thereby targeting the RAS/MAPK signaling pathway that is commonly activated in v...
公司完整简介财报意外
Verastem 已于 Aug 6, 2026 发布季度财报：
- 营收为 $40.08M 低于预期 $0, ， 1775.43% 同比增长.
- 每股收益为 -0.31 超出预期 0.14, ， 20.51% 同比增长.
第 1 页，共 2 页